Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

Documenti analoghi

• Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents
  di: Naoshi Nishida, et al.
  Pubblicazione: (2026)
• Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2025)
• Response to Letter to ‘Serum CRP in Durvalumab–Tremelimumab‐Treated HCC : Expanding the Inflammatory Narrative’
  di: Takeshi Hatanaka, et al.
  Pubblicazione: (2025)
• Response to Letter to ‘Serum CRP in Durvalumab‐Tremelimumab‐Treated HCC : Expanding the Inflammatory Narrative’
  di: Takeshi Hatanaka, et al.
  Pubblicazione: (2025)
• Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
  di: Keishi Ouchi, et al.
  Pubblicazione: (2026)